MedTrace Logo

High-Dose Vitamin D3 Supplementation in the Treatment of Human Immune Deficiency Virus Patients Trial

NCT05306704 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2022-04-11

No results posted yet for this study

Summary

High-Dose Vitamin D3 in the Treatment of Human Immune Deficiency Virus Patients, A Double-Blind Randomized Control Trial Human immunodeficiency virus is a key challenge for global health. Vitamin D deficiency is common in people living with HIV infection. Antiretroviral therapy may create unique risk factors for vitamin D insufficiency, including alterations of vitamin D metabolism by ART.

Conditions

Interventions

OTHER

placebo Oil

participants will receive placebo(olive oil) orally in all visits from visit 1 to visit 4

DRUG

25-Hydroxyvitamin D

Participants will receive vitamin D (100000IU) orally during all visits i.e. from visit-1 to visit-4

Sponsors & Collaborators

  • The National HIV/AIDS Programme

    collaborator OTHER_GOV

  • University of the Punjab

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-15
Primary Completion
2022-01-31
Completion
2022-01-31

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05306704 on ClinicalTrials.gov